Lotus Pharmaceutical is a generics pharmaceutical company, founded in 1966 and headquartered in Taiwan. The company became part of the Alvogen Group in 2014, and creates high-value generic products covering CNS, CVS, oncology, female health, and anti-obesity drugs in tablets & hard/softgel capsules, for markets all across the world. The primary focus of Lotus Pharmaceutical is addressing the fast-growing market of oncology. By aligning the company’s internal development and manufacturing capabilities, the company aims to benefit patients, its employees and shareholders alike. The company is proud of its best-in-class R&D and manufacturing platform, across Taiwan and Korea. Furthermore, Lotus Pharmaceutical can reach nearly every global market with its high value pipeline through the company’s direct markets relationship with Alvogen’s commercial units spanning over 30 countries, and through alliances with top-tier pharma companies. Lotus Pharmaceutical produces and promotes a unique portfolio of high quality and difficult-to-make pharmaceutical products, and it is these products which fuels its growth. The company offers high quality and affordable generic medications that help reduce healthcare costs for people across the globe. Lotus Pharmaceutical has more than 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, as well as more than 250 products in the market. The product portfolio of Lotus Pharmaceutical focuses on high growth difficult-to-make generics in the fields of oncology, cardiology, nephrology and central nervous system disease. On top of this, Lotus Pharmaceutical sells and markets a growing portfolio of OTC (over-the-counter) medicines and will be promoting the products of its partner Alvotech – a sister company in the Alvogen Group – and their biosimilar products in Asian markets once approved. The leadership team of is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of its customers. The organisational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.

Wuxi Hongrui Biomedical Technology Co., Ltd., established on 2010-02-21, Business scope includes medicine and medical equipment,Biochemicals,food,Production technology of chemical products and design of special equipment,to develop,Technical Services,Technical Training(Does not include certification);Training Services(Does not include certification,Does not include nationally recognized vocational certificate training);translation service;family service;Healthy food,food additives,Research and development of feed additives;Chemical raw materials and products(Does not contain dangerous goods),cosmetic,food,food additives,Sales of Feed Additives;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that are restricted by the state to be operated by enterprises or prohibited from import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

The Institute of Cancer Research is a British private company located in London that provides oncology treatment services.

Vernalis (R&D) Ltd. engages in the research development of biotechnology and pharmaceutical products manufacturing. The company was founded on February 4, 1986 and is headquartered in Wokingham, the United Kingdom.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

ANGECON performs cell development, manufacturing, sales, warehousing, and service. They create new cell medicines and offer a variety of cell treatments to people suffering from long-term conditions of the central nervous system. They have established a base for cell production demonstration using their cell technologies, including cell separation and purification, culture and expansion, cryopreservation and recovery, directional induction, identification, and testing.

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the 3rd company of its kind ever created, and has a rich tradition of innovation and commercialization. Through our efforts to identify and create breakthrough scientific research at Hebrew University, we aspire to advance commercial solutions to the most pressing global challenges facing humanity. (Contact Tamir Huberman) Some of our well-known spin-off companies include Mobileye, Orcam, Collplant, Qlight, and Briefcam. Yissum’s business partners span the globe and include companies such as Novartis, Johnson & Johnson, Merck, Intel, Google, Boston Scientific, ICL and many more. Since its inception, Yissum has registered 10,000+ patents covering 2,800+ inventions; licensed 900 technologies and produced 130+ spin-off companies.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Chongqing Yuanti Pharmaceutical Technology Co., Ltd., established on 2013-12-16, Business scope includes medical biotechnology research,technology development,technical consulting,Technology Transfer and Technical Services,Molecular Biology Reagent Research,technology development,Import and export,Technology Import and Export,Investment Management and Consulting(not to engage in banking,securities,Insurance and other financial services that require permission or approval),Sell ​​stationery,Office Supplies,Chemical Products(Free of Hazardous Chemicals and Class I Precursor Drugs),General Equipment,Teaching equipment and instruments,Class I medical device,Class II medical device,Class III Medical Devices.(The above business scope law,Prohibited by law,Not allowed to operate;law,regulations,Subject to approval by the State Council,Before approval,Not allowed to operate.)

Jinzhou Ahon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of medicine. Its products include calf serum deproteinized injection, penehyclidine hydrochloride injection, calf serum deproteinized enteric-coated capsules, glutamine granules, nervous system drugs, oncology drugs, perioperative drugs, and pediatric medicine. The company is headquartered in Jinzhou, China.

Zhongke Borui Beijing Technology Co. Ltd. (doing business as Casibrain Technology) is a Chinese company located in Beijing. The firm develops and supplies medical monitoring equipment. It was founded in 2017 by Xin Zhang.

AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY.

Shanghai Institutes for Biological Sciences CAS is a private company headquartered in Shanghai, China, that operates as researching agency.

Guangdong Yuanjian Biotechnology Co., Ltd., established on 2017-03-17, Business scope includes general business items:Research and development of compound microbial fertilizer;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of daily chemical products;R&D and application of cell technology;Traditional Chinese Medicine Health Care Services(non-medical);Cosmetics Wholesale;Cosmetics Retail;electronics sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license),The licensing program is:Sales of Class II Medical Devices;food business(Selling prepackaged food);Health food sales;Import and export agency;Food Internet Sales(Selling prepackaged food).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)